Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization of $246K in Q2 FY2026

Q2 FY2026 depreciation & amortization was $246K.

Context

  • Depreciation & amortization amounted to 59.6% of revenue in FY2025.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$246K+1.7% QoQ
Last fiscal yearDec 2025
$804K+156.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+156.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
804K USD
Year-over-year change
+156.9%
1-year CAGR
+156.9%

Depreciation & Amortization vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +156.9% is the 3rd highest of 10, against a peer median of +7.3%.
  • Depreciation & amortization amounts to 59.6% of revenue for ATTO, versus a peer median of 10.0%.
ATTO Competitors
Depreciation & Amortization for ATTO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$3.08M USD+50.1%+151.3%—
ALMSAlumis Inc. Common StockLTM Jun 2026$2.65M USD-20.7%+140.9%35.9%
ANABAnaptysBio, Inc.LTM Mar 2026$2.43M USD+1.2%+1.2%1.0%
EVMNEvommune, Inc.LTM Mar 2026$1.36M USD——13.6%
ATTOAttovia Therapeutics, Inc.FY2025$804K USD+156.9%—59.6%
CNTBConnect Biopharma Holdings LimitedFY2025$704K USD+6.7%-11.9%1100.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$528K USD+7.3%-17.1%6.3%
QTTBQ32 Bio Inc.LTM Mar 2026$362K USD-25.1%+1.9%0.7%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€311K EUR+214.1%——
ORKAOruka Therapeutics, Inc.LTM Sep 2026$163K USD+129.6%-10.0%—
ZURAZura Bio LimitedLTM Mar 2026$56K USD+211.1%——
Peer median (excluding ATTO) —+7.3%+1.2%10.0%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.35M
Cost of Revenue313K804K
Gross Profit(313K)546K
Gross Margin—40.4%
Research & Development33.86M54.15M
Selling, General & Admin7.38M13.55M
Operating Expenses41.24M67.71M
Depreciation & Amortization313K804K
EBITDA(41.24M)(66.36M)
EBITDA Margin—-4915.2%
Operating Income(41.55M)(67.16M)
Operating Margin—-4974.7%
Interest Income3.44M6.63M
Interest Expense00
Other Income / Expenses1.75M6.53M
Income Before Tax(39.8M)(60.63M)
Pre-Tax Margin—-4490.9%
Income Tax Expense00
Net Income(39.8M)(60.63M)
Net Margin—-4490.9%
EPS (Basic)(1.05)(1.42)
EPS (Diluted)(1.05)(1.42)
Weighted Avg Shares43.03M43.03M
Weighted Avg Shares (Diluted)43.03M43.03M

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.